Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | Director | June 11, 2021 | June 15, 2021 |
| Olema Pharmaceuticals, Inc.OLMA · Entity 613 | Director | June 18, 2026 | June 23, 2026 |
| Science 37 Holdings, Inc.LSAQ · Entity 15235 | Director | November 20, 2020 | November 20, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date June 11, 2021 · Filed June 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.66 · Expires 2031-06-10 | Direct | 12,004 |
Reported balance
After 2021-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-11 · Grant · Acquired 12,004 · Balance 12,004 F1: Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders.
Olema Pharmaceuticals, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.51 · Expires 2036-06-18 | Direct | 29,500 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 29,500 · Balance 29,500 F1: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.
Science 37 Holdings, Inc.
Report date November 20, 2020 · Filed November 20, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2020-11-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,000 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akero Therapeutics, Inc.
Report date December 09, 2025 · Filed December 09, 2025
Section 16 reporting ended · disclosed 2025-12-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2025-12-09 · Disposition to issuer · Disposed 93,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2025-12-09 · Disposition to issuer · Disposed 9,398 · Balance 0 F3: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU. F4: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2025-12-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-12-09 · Disposition to issuer · Disposed 1,200,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration"). F2: The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.83 · Expires 2033-06-23 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-09 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration").
F2: The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F3: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 21:21 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (right to buy) · Derivative | 29,500 | $0.00 Strike: $9.51 | $0.00 |
DisclosureSEC source: 0001777517-26-000002 · form4-06232026_090610.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,500 Underlying: Common Stock · 29,500 shares Expires 2036-06-18 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| December 09, 2025 Filed Dec 9, 2025 10:17 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $50.83 | Not disclosed |
DisclosureSEC source: 0001193125-25-312122 · ownership.xml · derivative · entry 4 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2033-06-23 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Read SEC document |
| December 09, 2025 Filed Dec 9, 2025 10:17 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Disposition to issuerCommon Stock | 9,398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-312122 · ownership.xml · nonDerivative · entry 3 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · shares: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU. Read SEC document |
| December 09, 2025 Filed Dec 9, 2025 10:17 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Disposition to issuerCommon Stock | 1,200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-312122 · ownership.xml · nonDerivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration"). F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration"). F2 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 09, 2025 Filed Dec 9, 2025 10:17 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Disposition to issuerCommon Stock | 93,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-312122 · ownership.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration"). F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration"). Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 19:48 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,832 | $0.00 Strike: $19.97 | $0.00 |
DisclosureSEC source: 0001193125-25-237295 · ownership.xml · derivative · entry 11 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,832 shares Expires 2029-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 19:48 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $25.20 | $0.00 |
DisclosureSEC source: 0001193125-25-237295 · ownership.xml · derivative · entry 10 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires 2030-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 19:48 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $26.32 | $0.00 |
DisclosureSEC source: 0001193125-25-237295 · ownership.xml · derivative · entry 9 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires 2031-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 19:48 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $8.13 | $0.00 |
DisclosureSEC source: 0001193125-25-237295 · ownership.xml · derivative · entry 8 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2032-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 19:48 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $23.02 | $0.00 |
DisclosureSEC source: 0001193125-25-237295 · ownership.xml · derivative · entry 7 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,000 shares Expires 2034-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 19:48 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 23,832 | $19.97 | $475,925.04 |
DisclosureSEC source: 0001193125-25-237295 · ownership.xml · nonDerivative · entry 5 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 19:48 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 13,000 | $25.20 | $327,600.00 |
DisclosureSEC source: 0001193125-25-237295 · ownership.xml · nonDerivative · entry 4 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 19:48 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 13,000 | $26.32 | $342,160.00 |
DisclosureSEC source: 0001193125-25-237295 · ownership.xml · nonDerivative · entry 3 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 19:48 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 15,000 | $8.13 | $121,950.00 |
DisclosureSEC source: 0001193125-25-237295 · ownership.xml · nonDerivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 19:48 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 26,000 | $23.02 | $598,520.00 |
DisclosureSEC source: 0001193125-25-237295 · ownership.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (right to buy) · Derivative | 24,150 | $0.00 Strike: $4.08 | $0.00 |
DisclosureSEC source: 0001415889-25-017235 · form4-06132025_050617.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,150 Underlying: Common Stock · 24,150 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 16:05 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantCommon Stock | 9,398 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-082306 · ownership.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,566 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs shall vest in full on the earlier of (i) June 3, 2026, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board. Read SEC document |
| March 27, 2025 Filed Mar 27, 2025 19:42 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 50,000 | $43.55 | $2,177,700.00 |
DisclosureSEC source: 0000950170-25-046271 · ownership.xml · nonDerivative · entry 3 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote 1 Disclosed balance after: 1,200,000 F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 26, 2025 Filed Mar 27, 2025 19:42 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 58,691 | $43.01 | $2,524,417.29 |
DisclosureSEC source: 0000950170-25-046271 · ownership.xml · nonDerivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote 1 Disclosed balance after: 1,150,000 F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 25, 2025 Filed Mar 27, 2025 19:42 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 91,309 | $44.75 | $4,085,803.82 |
DisclosureSEC source: 0000950170-25-046271 · ownership.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote 1 Disclosed balance after: 1,091,309 F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 30, 2025 Filed Feb 7, 2025 19:54 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 200,000 | $48.00 | $9,600,000.00 |
DisclosureSEC source: 0000950170-25-016559 · ownership.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,000,000 F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 17, 2024 Filed Dec 18, 2024 00:52 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | PurchaseCommon Stock | 700,761 | $6.75 | $4,730,136.75 |
DisclosureSEC source: 0000935836-24-000763 · ownership.xml · nonDerivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 1,408,875 F3 · kind: These securities were sold by Logos Fund I to Logos Fund IV. Logos Fund I and Logos Fund IV are under the common control of the Reporting Person. F2 · ownership.nature: The shares are held by Logos Opportunities Fund IV LP ("Logos Fund IV"). Logos Opportunities IV GP LLC ("GP IV") is the general partner of Logos Fund IV and the reporting person is a managing member of GP IV. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 17, 2024 Filed Dec 18, 2024 00:52 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 700,761 | $6.75 | $4,730,136.75 |
DisclosureSEC source: 0000935836-24-000763 · ownership.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 0 F3 · kind: These securities were sold by Logos Fund I to Logos Fund IV. Logos Fund I and Logos Fund IV are under the common control of the Reporting Person. F1 · ownership.nature: The shares are held by Logos Opportunities Fund I LP ("Logos Fund I"). Logos Opportunities GP, LLC ("Logos Opportunities GP") is the general partner of Logos Fund I and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 23:52 UTC Amendment | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | PurchaseCommon Stock | 700,761 | $6.75 | $4,730,136.75 |
DisclosureSEC source: 0000935836-24-000764 · ownership.xml · nonDerivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 700,761 F5 · security: The Form 4 filed on December 17, 2024, inadvertently reported the number of shares held by Logos Fund IV after the transaction as 1,408,875. As reported in this amended Form 4, the number of shares held by Logos Fund IV after the transaction is 700,761. The Form 4 also mistakenly reported the purchase of shares by Logos Fund IV as a disposition. The transaction was an acquisition. The transaction date was December 13, 2024. F3 · kind: These securities were sold by Logos Fund I to Logos Fund IV. Logos Fund I and Logos Fund IV are under the common control of the Reporting Person. F2 · ownership.nature: The shares are held by Logos Opportunities Fund IV LP ("Logos Fund IV"). Logos Opportunities IV GP LLC ("GP IV") is the general partner of Logos Fund IV and the reporting person is a managing member of GP IV. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 23:52 UTC Amendment | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 700,761 | $6.75 | $4,730,136.75 |
DisclosureSEC source: 0000935836-24-000764 · ownership.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 0 F4 · security: The Form 4 filed on December 17, 2024 identified the transaction date as December 17, 2024. The transaction date was December 13, 2024. F3 · kind: These securities were sold by Logos Fund I to Logos Fund IV. Logos Fund I and Logos Fund IV are under the common control of the Reporting Person. F1 · ownership.nature: The shares are held by Logos Opportunities Fund I LP ("Logos Fund I"). Logos Opportunities GP, LLC ("Logos Opportunities GP") is the general partner of Logos Fund I and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0001415889-24-017448 · form4-06182024_050620.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2034-06-14 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 08, 2024 Filed Jun 11, 2024 17:29 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $23.02 | $0.00 |
DisclosureSEC source: 0000950170-24-072077 · ownership.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2034-06-07 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) June 7, 2025, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 21:01 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 475,000 | $14.85 | $7,053,750.00 |
DisclosureSEC source: 0000935836-24-000425 · ownership.xml · nonDerivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 708,114 F2 · ownership.nature: The shares are held by Logos Opportunities Fund II LP ("Logos Fund II"). Logos Opportunities GP is the general partner of Logos Fund II and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 21:01 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 700,000 | $14.85 | $10,395,000.00 |
DisclosureSEC source: 0000935836-24-000425 · ownership.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 700,761 F1 · ownership.nature: The shares are held by Logos Opportunities Fund I LP ("Logos Fund I"). Logos Opportunities GP, LLC ("Logos Opportunities GP") is the general partner of Logos Fund I and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 04, 2024 Filed Nov 26, 2024 21:48 UTC Amendment | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 475,000 | $14.85 | $7,053,750.00 |
DisclosureSEC source: 0000935836-24-000744 · ownership.xml · nonDerivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 708,114 F2 · ownership.nature: The shares are held by Logos Opportunities Fund II LP ("Logos Fund II"). Logos Opportunities GP is the general partner of Logos Fund II and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 04, 2024 Filed Nov 26, 2024 21:48 UTC Amendment | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 700,000 | $14.85 | $10,395,000.00 |
DisclosureSEC source: 0000935836-24-000744 · ownership.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 700,761 F1 · ownership.nature: The shares are held by Logos Opportunities Fund I LP ("Logos Fund I"). Logos Opportunities GP, LLC ("Logos Opportunities GP") is the general partner of Logos Fund I and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 08, 2023 Filed Dec 11, 2023 21:06 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 50,000 | $19.85 | $992,700.00 |
DisclosureSEC source: 0000950170-23-069509 · ownership.xml · nonDerivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 800,000 F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 08, 2023 Filed Dec 11, 2023 21:06 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 50,000 | $19.80 | $990,240.00 |
DisclosureSEC source: 0000950170-23-069509 · ownership.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 750,000 F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 05, 2023 Filed Dec 18, 2023 23:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | PurchaseCommon Stock | 50,000 | $13.09 | $654,250.00 |
DisclosureSEC source: 0000935836-23-000733 · ownership.xml · nonDerivative · entry 4 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 1,800,000 F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the reporting person is a managing member of Logos GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 05, 2023 Filed Dec 18, 2023 23:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | PurchaseCommon Stock | 50,000 | $14.95 | $747,480.00 |
DisclosureSEC source: 0000935836-23-000733 · ownership.xml · nonDerivative · entry 3 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 1,750,000 F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the reporting person is a managing member of Logos GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 05, 2023 Filed Dec 18, 2023 23:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | PurchaseCommon Stock | 31,870 | $14.73 | $469,550.27 |
DisclosureSEC source: 0000935836-23-000733 · ownership.xml · nonDerivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 1,700,000 F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the reporting person is a managing member of Logos GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 08:37 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 50,000 | $16.99 | $849,730.00 |
DisclosureSEC source: 0000950170-23-067951 · ownership.xml · nonDerivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 700,000 F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 30, 2023 Filed Dec 5, 2023 08:37 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 50,000 | $16.90 | $844,835.00 |
DisclosureSEC source: 0000950170-23-067951 · ownership.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 650,000 F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 19, 2023 Filed May 23, 2023 21:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 400,000 | $26.00 | $10,400,000.00 |
DisclosureSEC source: 0000950170-23-023738 · ownership.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 400,000 F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 12, 2023 Filed Dec 18, 2023 23:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | PurchaseCommon Stock | 508,130 | $9.84 | $4,999,999.20 |
DisclosureSEC source: 0000935836-23-000733 · ownership.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 1,668,130 F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the reporting person is a managing member of Logos GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 16:46 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 25,000 | $42.06 | $1,051,475.00 |
DisclosureSEC source: 0000950170-23-041440 · ownership.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 600,000 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $41.8634 to $42.3525, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. F2 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 01, 2023 Filed Aug 1, 2023 19:52 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 25,000 | $43.26 | $1,081,525.00 |
DisclosureSEC source: 0000950170-23-036694 · ownership.xml · nonDerivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 575,000 F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 28, 2023 Filed Aug 1, 2023 19:52 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 30,000 | $42.69 | $1,280,709.00 |
DisclosureSEC source: 0000950170-23-036694 · ownership.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 550,000 F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 17:48 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $50.83 | $0.00 |
DisclosureSEC source: 0000950170-23-030214 · ownership.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-06-22 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 23, 2024 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (right to buy) · Derivative | 21,520 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0001415889-23-010103 · form4-06212023_050607.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2033-06-15 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| May 19, 2023 Filed May 23, 2023 21:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 120,000 | $42.00 | $5,040,000.00 |
DisclosureSEC source: 0000950170-23-023738 · ownership.xml · nonDerivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 520,000 F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 19, 2023 Filed Jun 15, 2023 21:26 UTC Amendment | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 120,000 | $42.00 | $5,040,000.00 |
DisclosureSEC source: 0000899243-23-015665 · doc4a.xml · nonDerivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 520,000 F2 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 19, 2022 Filed Jun 15, 2023 21:26 UTC Amendment | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 400,000 | $26.00 | $10,400,000.00 |
DisclosureSEC source: 0000899243-23-015665 · doc4a.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 400,000 F1 · date: This Form 4 amendment is being filed solely to correct the original Form 4 filed on May 23, 2023, which inadvertently included the incorrect transaction date of September 19, 2023, due to a clerical error. This amendment corrects the date of the transaction to September 19, 2022. F2 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 17, 2022 Filed Jun 27, 2022 21:10 UTC Amendment | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (right to buy) · Derivative | 21,520 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001415889-22-006961 · form4a-06272022_020606.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2032-06-16 F1 · derivative.exercise_price: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein. F1 · date: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein. F2 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 23:25 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (right to buy) · Derivative | 21,520 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001415889-22-006782 · form4-06172022_040626.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2032-06-15 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.